|Bid||0.000 x 1400|
|Ask||0.550 x 900|
|Day's Range||0.3800 - 0.4000|
|52 Week Range||0.3800 - 0.8300|
|Beta (3Y Monthly)||3.35|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 10, 2016 - Mar 14, 2016|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.30|
Protalix (PLX) delivered earnings and revenue surprises of -150.00% and -91.71%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Carmiel, Israel-based company said it had a loss of 10 cents. The drug developer posted revenue of $663,000 in the period. The company's shares closed at 49 cents. A year ago, ...
CARMIEL, Israel, Nov. 07, 2018 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of.
Protalix (PLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CARMIEL, Israel, Oct. 29, 2018 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of.
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 3) Amarin Corporation plc (NASDAQ: AMRN ) BIOLINERX Ltd/S ...
~Preliminary Results Indicate Significant Improvement in Kidney Function in Patients Switched from agalsidase alfa (Replagal®) to pegunigalsidase alfa (PRX-102)~ A.
Biotech shares saw further momentum last week, following up on the gains of the previous two weeks. Will the momentum continue in the upcoming week? Here are the catalytic events that could drive the sector. ...
NEW YORK, NY / ACCESSWIRE / September 24, 2018 / Shares of GTx were deep in the red on Friday on disappointing news that the company’s only drug candidate had filed a mid-stage clinical trial. Shares of Protalix BioTherapeutics on the other hand were soaring on positive preliminary data. GTx, Inc. shares closed down a little over 92% on Friday, making it one of the biggest decliners on the Nasdaq.
Preliminary Results Indicate Improvement in Kidney Function in Patients Switched from agalsidase alfa to pegunigalsidase alfa. A deterioration trend in patients’ kidney function on agalsidase alfa was ...
CARMIEL, Israel, Sept. 17, 2018-- Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its ...
Protalix (PLX) delivered earnings and revenue surprises of -33.33% and -71.34%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
In this article, I will take a quick look at Protalix BioTherapeutics Inc’s (NYSEMKT:PLX) recent ownership structure – an unconventional investing subject, but an important one. The impact of aRead More...
On a per-share basis, the Carmiel, Israel-based company said it had a loss of 8 cents. The drug developer posted revenue of $2 million in the period. The company's shares closed at 50 cents. A year ago, ...
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Protalix Biotherapeutics, Inc. (NYSE: PLX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 8:30 AM Eastern ...
LONDON, UK / ACCESSWIRE / July 31, 2018/ If you want a free Stock Review on SRPT sign up now at www.wallstequities.com/registration. Losses were broad based as seven out of nine sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Protalix BioTherapeutics Inc. (NYSE AMER: PLX), Radius Health Inc. (NASDAQ: RDUS), Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), and Sarepta Therapeutics Inc. (NASDAQ: SRPT).
On July 24, Protalix BioTherapeutics (PLX) expanded its partnership with Chiesi Farmaceutici. The expansion of the agreement allows Chiesi Farmaceutici exclusive US license for the development and commercialization of PRX-102 (pegunigalsidase alfa), which is Protalix’s modified version of the recombinant alpha-galactosidase-A protein. In October 2017, Protalix and Cheisi entered an exclusive partnership for the development and commercialization of PRX-102 outside the US for the treatment of individuals with Fabry disease.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Protalix Biotherapeutics Inc (NYSE: PLX ) stock gained ...